Catheter Precision, Inc. Files Form 10-K/A Amendment: Key Disclosures for Investors

Catheter Precision, Inc. (NYSE American: VTAK) has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment provides important updates and expanded disclosures that are highly relevant to shareholders and could impact the company’s share price. Below is a comprehensive overview of the key points and material details investors must know.

Key Highlights from the 10-K/A Filing

• Purpose of the Amendment: The amendment was filed to provide additional information previously omitted from the original Form 10-K under Part III, Item 13, particularly regarding related party transactions and director independence. This follows General Instruction G(3) to Form 10-K, allowing such information to be included by later amendment instead of the proxy statement.
• Nature of Filing: The 10-K/A is designated as an “Annual Report” and not a “Transition Report.” The amendment clarifies that it does not include new financial statements, nor does it update previously reported financial information, except as specifically amended.
• Financial and Capital Structure Snapshot:
  • Public Float: As of June 30, 2024, the aggregate market value of common stock held by non-affiliates was approximately \$3.9 million.
  • Shares Outstanding: As of March 20, 2026, there were 2,692,473 shares of common stock (par value \$0.0001) outstanding.
  • Exchange and Symbol: Shares trade on the NYSE American under the symbol VTAK.
• Company Classification:
  • Filer Status: Non-accelerated filer.
  • Smaller Reporting Company: Yes.
  • Emerging Growth Company: No.
  • Well-Known Seasoned Issuer: No.
  • Shell Company: No.
• Compliance Certification: The company affirms it has filed all required reports under Section 13 or 15(d) of the Exchange Act for the previous 12 months and has submitted all required interactive data files.

Material Related Party Transactions

The amendment provides extensive disclosure on “Related Person Transactions” pursuant to Item 404(d) of Regulation S-K. For Catheter Precision, Inc., any transaction exceeding \$120,000 in which an executive officer, director, significant shareholder (over 5%), or immediate family member has a direct or indirect material interest must be disclosed.

• Royalty Right Exchange and Series J Preferred Stock Issuance:
  • The company entered into a significant transaction involving the exchange of certain royalty rights for the issuance of Series J Convertible Preferred Stock. This transaction involved related parties and may impact future dilution and the company’s capital structure.
  • The disclosure clarifies that all related party transactions were approved in accordance with company policies and asserts that the terms were as favorable as those obtainable from third parties.

Director Independence and Corporate Governance

• NYSE American Compliance: The company confirms it adheres to NYSE American listing standards, including having a majority of independent directors and ensuring all audit, compensation, and nominating/corporate governance committees are composed entirely of independent directors.
• Board Assessment: The Board of Directors evaluated all non-employee directors for independence, considering business and family relationships, and confirmed their status as independent under NYSE American rules.

Other Key Disclosures

• Internal Controls: The amendment states that no new financial statements are included and there are no changes to management’s assessment of internal controls, nor are there auditor attestation reports under Section 404(b) of Sarbanes-Oxley.
• Restatements & Compensation Clawbacks: The company affirms that the financial statements do not reflect any corrections of prior errors, and no compensation clawbacks under Rule 10D-1(b) were required.
• Exhibits Filed: Certifications by both the principal executive officer and the principal financial officer (Philip Anderson) are included as exhibits to the amendment, but paragraphs 3, 4, and 5 of the certifications were omitted as no financial information was restated.

Potential Shareholder Impact and Price Sensitivity

• Corporate Transactions: The disclosure of the exchange of royalty rights for Series J Convertible Preferred Stock directly impacts the company’s capital stack and could lead to future dilution. Shareholder approval for the issuance of common stock upon conversion of the Series J Preferred Stock and upon exercise of the Series M Warrants is required. Failure or delays in obtaining such approval may have material implications for the company’s financing and strategic direction.
• Forward-Looking Statements: The company made statements regarding the anticipated approval of certain transactions by shareholders, future product development (Cardionomix and KardioNav), and the ability to meet obligations under related party notes. All such statements are subject to risks, as described in the company’s risk factors.
• Governance and Compliance: Affirmation of compliance with NYSE American governance standards and filing obligations may enhance investor confidence, but any future lapses could negatively affect the share price.

Conclusion

This Form 10-K/A amendment is significant for shareholders as it provides further transparency on related party transactions, board independence, and the company’s compliance with regulatory requirements. The disclosure of the Series J Preferred Stock transaction, in particular, is potentially price sensitive due to its impact on capital structure and future dilution. Investors should closely monitor upcoming proxy materials for more detailed information on these matters and for any required shareholder actions regarding approval of stock issuances linked to the Series J and Series M securities.

Disclaimer: This article is a summary and interpretation of Catheter Precision, Inc.’s Form 10-K/A amendment and is provided for informational purposes only. It does not constitute investment advice or an offer to buy or sell securities. Investors should review the full SEC filings and consult their financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties as detailed in the company’s filings.

View Catheter Precision, Inc. Historical chart here